3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Phase 2
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
3
Endocrine
3
Thoracic
2
Plasma cell
2
Other hematologic neoplasm
2
Myeloid
2
Gynecologic
2
Gastrointestinal
2
CNS
2
Lymphoid
1
Dermatologic
1
Conditions
Multiple Myeloma
28
Neoplasms, Plasma Cell
9
Neoplasms
7
Lymphoma
6
Leukemia
6
Infections
5
Hematologic Neoplasms
4
Thyroid Carcinoma, Anaplastic
2
Thyroid Cancer, Papillary
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Laryngeal Neoplasms
2
Granuloma, Plasma Cell
2
Glioma
2
Erdheim-Chester Disease
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Sarcoma, Synovial
1
Sarcoma, Clear Cell
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Perivascular Epithelioid Cell Neoplasms
1
Neurofibrosarcoma
1
Nerve Sheath Neoplasms
1
Nephrotic Syndrome
1
Neoplasm Metastasis
1
Interventions
trametinib
1
dabrafenib
1
cobimetinib
1
Vemurafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Thyroid Carcinoma, Anaplastic
×
Plasma cell
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled